









Markets
/
Stocks
/
nasdaq-dawn
/

Day One Biopharmaceuticals Inc

DAWN

21.400USD

+0.030+0.14%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

1.29BMarket Cap

LossP/E TTM



Day One Biopharmaceuticals Inc

21.400

+0.030+0.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Day One Biopharmaceuticals Inc

Currency: USD Updated: 2026-03-26

Key Insights

Day One Biopharmaceuticals Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 6 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 20.75.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Day One Biopharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

6 / 391

Overall Ranking

48 / 4546

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Day One Biopharmaceuticals Inc Highlights

StrengthsRisks

Day One Biopharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing targeted therapies for people of all ages with life-threatening diseases. The Company partners with clinical oncologists, families, and scientists to identify, acquire, and develop cancer treatments. The Company’s commercial product, OJEMDA (tovorafenib), is an oral, brain-penetrant, selective type II rapidly accelerated fibrosarcoma (RAF) kinase inhibitor of mutant BRAF V600, wild-type BRAF, and wild-type CRAF kinases. Its pipeline product candidates include DAY301 and VRK1 program. The DAY301 candidate is a PTK7 targeted ADC composed of a novel humanized anti-PTK7 immunoglobulin G1 monoclonal antibody (mAb), conjugated with a topoisomerase I inhibitor through a stable and hydrophilic modified valine-alanine (VA) cleavable linker. Its VRK1 program is a novel target involved in the regulation of cell division and DNA damage repair.

Undervalued

The company’s latest PE is -20.58, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 86.52M shares, increasing 0.09% quarter-over-quarter.

Held by Paul Tudor Jones

Star Investor Paul Tudor Jones holds 62.32K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.76.

Analyst Rating

Based on 8 analysts

Hold

Current Rating

20.750

Target Price

-2.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Day One Biopharmaceuticals Inc is 8.50, ranking 37 out of 391 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 53.72M, representing a year-over-year increase of 83.92%, while its net profit experienced a year-over-year increase of 67.62%.

Score

Industry at a Glance

Previous score

8.50

Change



Financials

9.46

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.10

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.88

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.42

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Day One Biopharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Day One Biopharmaceuticals Inc is 7.27, ranking 138 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -20.58, which is -79.51% below the recent high of -4.22 and -0.19% above the recent low of -20.62.

Score

Industry at a Glance

Previous score

7.27

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 6/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Day One Biopharmaceuticals Inc is 8.22, ranking 153 out of 391 in the Biotechnology & Medical Research industry. The average price target is 22.50, with a high of 29.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

6.00

Change

2.22

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Hold

Current Rating

20.750

Target Price

-2.95%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Day One Biopharmaceuticals Inc

DAWN

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Day One Biopharmaceuticals Inc is 9.90, ranking 1 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 25.25 and the support level at 13.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.78

Change

0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.188

Neutral

RSI(14)

81.467

Overbought

STOCH(KDJ)(9,3,3)

66.822

Neutral

ATR(14)

0.091

Low Volatility

CCI(14)

132.275

Buy

Williams %R

22.222

Buy

TRIX(12,20)

2.661

Sell

StochRSI(14)

9.692

Oversold

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

21.390

Buy

MA10

21.361

Buy

MA20

18.830

Buy

MA50

14.390

Buy

MA100

11.681

Buy

MA200

9.310

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Day One Biopharmaceuticals Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 115.65%, representing a quarter-over-quarter decrease of 3.49%. The largest institutional shareholder is The Vanguard, holding a total of 6.27M shares, representing 6.07% of shares outstanding, with 3.74% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Access Industries, Inc.

12.93M

BlackRock Institutional Trust Company, N.A.

6.43M

-5.43%

Atlas Venture

6.43M

The Vanguard Group, Inc.

Star Investors

6.17M

+0.08%

Vestal Point Capital, LP

2.67M

-10.83%

State Street Investment Management (US)

3.24M

+20.48%

Deerfield Management Company, L.P.

4.71M

+26.38%

Fidelity Management & Research Company LLC

7.61M

-17.27%

Pictet Asset Management Ltd.

2.37M

-36.25%

Blackman (Samuel C)

2.04M

+0.50%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Day One Biopharmaceuticals Inc is 4.22, ranking 96 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is -1.72. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.